A phase I trial of the combination of sirolimus and SU11248 (Sutent(R)) [sunitinib] in patients with advanced solid tumors that are non-curable with standard therapy

Trial Profile

A phase I trial of the combination of sirolimus and SU11248 (Sutent(R)) [sunitinib] in patients with advanced solid tumors that are non-curable with standard therapy

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Sirolimus; Sunitinib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Dec 2013 Status changed from active, no longer recruiting to discontinued.
    • 03 Oct 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top